Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations CRM IHD SEG101 - P-Selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion + Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients ≥12 year old) NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease (SCD) Phase 3 240 Rate of VOC events leading to healthcare visit Crizanlizumab 5.0 mg/kg Crizanlizumab 7.5 mg/kg Placebo Adolescent and adult SCD patients (12 years and older) 2022 Publication 2024 (pediatric patients <12 year old) Planned abstract submission to congress in H2-2021 TBD 113 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation